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Abstract
We studied the putative significance of angiotensin
I–converting enzyme (ACE) in colorectal cancer (CRC)
biology. Local expression of ACE was investigated by
quantitative reverse transcription–polymerase chain
reaction and by immunohistochemistry in CRCs and
adenomas. ACE insertion (I)/deletion (D) polymorphism
was studied in 141 CRC patients and 189 controls. ACE
mRNA was upregulated in CRCs compared to corre-
sponding nonlesional tissues (2.5-fold; P = .009). ACE
protein was more commonly expressed in adenomas
[17 (81%)] and cancer epithelial cells [22 (100%)] than in
corresponding non-neoplastic crypt and surface epi-
thelium [2 (10%) and 2 (9%), respectively]. Thirty-seven
CRC patients (26%) carried II genotype, 69 (49%) carried
ID genotype, and 35 (25%) carried DD genotype. The
distribution of the genotypes did not differ from that of
controls. Female CRC patients more commonly carried
the ID genotype and less frequently the II and DD ge-
notypes compared with male patients (P = .033). Men
heterozygous or homozygous for the D-allele had larger
tumors compared to carriers of the II genotype (P < .01).
Women homozygous for the D-allele lived longer than
carriers of the ID and II genotypes. Our study shows that
ACE is differentially expressed in CRCs and that gene
polymorphism is associated with gender-specific differ-
ences in primary tumor size and patient survival.
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Introduction
Angiotensin I–converting enzyme (ACE; CD143) is a type I
cell surface zinc metallopeptidase that is expressed by
many cell types of various organs and tissues, including vas-
cular endothelial cells, epithelial cells of the small intestine,
kidney tubular cells, mononuclear cells, and fibroblasts [1]. ACE
cleaves C-terminal dipeptides from oligopeptide substrates with
an unhindered C-terminus. It generates angiotensin II, the major
effector of the renin–angiotensin system, and cleaves angio-
tensin 1–9 into angiotensin 1–7. There is mounting evidence
that ACE participates locally in the pathology of carcinomas
[1,2]. ACE is differentially expressed in several malignancies [1]
and influences tumor cell proliferation, tumor cell migration,
angiogenesis, and metastatic behavior [2–4]. Inhibition of ACE
activity influences tumor growth and angiogenesis in vitro and
in vivo in animal models [5–10]. Epidemiological studies have
provided evidence that ACE inhibitorsmay decrease the risk and
mortality rate of cancer [11,12]. ACE inhibitors are currently
under consideration as ‘‘novel’’ antineoplastic treatment and
cancer prevention strategies [2,12]. A polymorphism in the
ACE gene, consisting of the insertion (I) or the deletion (D) of
a 287-bp DNA fragment in intron 16, accounts for 20% to 50% of
the variance in ACE expression or activity in blood and tissues
among individuals [13–15]. Recently, we have shown that ACE
is expressed locally in gastric cancer [16] and that I/D gene
polymorphism influences metastatic behavior [17]. Patients with
DD genotype had a greater number of lymph node metastases
and an advanced Union International Contre le Cancer (UICC)
tumor stage compared with carriers of ID or II genotype [17].
Furthermore, a retrospective study provided evidence that
long-term ACEmedication decreases the risk of developing co-
lorectal cancer (CRC) [18]. Intrigued by these observations, we
aimed to further substantiate the putative significance of ACE
by investigating its local expression in colorectal adenomas
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and CRCs and by correlating its gene polymorphism with
CRC pathology.
Materials and Methods
Patient Populations and Samples
Samples from 141 CRC patients and 21 patients with
colorectal adenomas operated on between 2001 and 2006
were retrieved from the archive of the Department of Pa-
thology (Table 1). Tissue samples used in the present study
were obtained from patients who had undergone either
polypectomy or right/left–sided hemicolectomy, as well as
from 189 control patients without CRC, as described previ-
ously (Table 1) [17]. This study was carried out in accor-
dance with the guidelines of the Ethics Committee of the
University Hospital Berlin, and the patients gave their in-
formed consent before their inclusion in the study. Data were
encoded to ensure patient protection.
Histology and Immunohistochemistry
For histology, tissue samples from all patients were fixed
in 10% neutralized formalin and embedded in paraffin. De-
paraffinized sections were stained using hematoxylin and
eosin. Tumor–Node–Metastasis stage was determined ac-
cording to UICC guidelines and was based on histologic con-
firmation [19]. For immunohistochemical studies, samples
from a series of 22 consecutive patients with CRC and 21
randomly chosen patients with colorectal adenomas were
used. Immunostaining was performed as described else-
where, using monoclonal antibodies directed against ACE
(clone CG2, 1:50; Dianova, Hamburg, Germany) [16]. Omis-
sion of primary antibodies served as negative control.
Quantitative Real-Time Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
To measure ACEmRNA expression levels, total RNA was
extracted from frozen tissues using Trizol reagent (Invitro-
gen, Karlsruhe, Germany), followed by the RNeasy Kit
(Qiagen, Hilden, Germany) for mRNA preparation, according
to the manufacturer’s instructions. cDNA was synthesized
from 1 mg of RNA using Omniscript Reverse Transcriptase
(Qiagen), and quantitative real-time RT-PCR was performed
using LightCycler (Roche Diagnostics, Mannheim, Germany).
A 20-ml reactionmixture consisted of 10 ml of Quantitect SYBR
Green MasterMix (Qiagen), 2 ml of cDNA, and 1 mM of specific
primers for ACE (forward: CTCAAGTACTTCCAGCCAGTC;
reverse: GCAGAATCTTGCTGGTCTCTG; product, 371 bp)
or b-actin (forward: CATGTACGTTGCTATCCAGGC; reverse:
CTCCTTAATGTCACGCACGAT; product, 250 bp). The initial
denaturation and activation of Taq polymerase at 95jC for
15 minutes were followed by 40 cycles with denaturation at
94jC for 15 seconds, annealing at 62jC for 20 seconds, and
elongation at 72jC for 20 seconds (ACE) or 15 seconds
(b-actin), followed by a melting curve analysis between
65jC and 95jC to verify the absence of primer artifacts. Only
samples without primer artifacts were included in the analy-
ses. Specific initial template mRNA amounts were calculated
as described above from a standard curve obtained by serial
dilution of known copy numbers of corresponding cloned
PCR fragments. cDNA contents were normalized for any
variability in RNA amounts or for integrity by calculating the
ACE/b-actin ratio.
Determination of ACE Genotype
Genomic DNA was purified from non-neoplastic tissue
specimens using the EZNA Tissue DNA Mini Kit (PEQLAB
Biotechnologie GmbH, Elangen, Germany). DNA was dis-
solved at 100 ng/ml in 10 mM Tris–HCl and 1 mM EDTA, pH
8.0. The ACE genotype of patients and healthy controls was
determined by PCR according to Yoshida et al. [20]. A typical
Table 1. Patient Characteristics.
I/D Genotype
Total II ID DD P
Controls
Patients [n (%)] 189 41 (22) 95 (49) 53 (28)
Age in years
[mean ± SD]
67.7 ± 6.1 69.2 ± 6.2 67.9 ± 6.4 65.8 ± 5.0 ns
Gender [n (%)]
Men 75 (40) 17 (23) 38 (51) 20 (27) ns
Women 114 (60) 24 (21) 57 (50) 33 (29)
Colon cancer patients
Patients [n (%)] 141 37 (26) 69 (49) 35 (25) ns
Age in years
[mean ± SD]
66.7 ± 12.4 66.1 ± 13.0 67.9 ± 10.7 65.2 ± 14.7 ns
Gender [n (%)]
Men 83 (59) 26 (31) 33 (40) 24 (29) .033
Women 58 (41) 11 (19) 36 (62) 11 (19)
Localization [n (%)]
Colon 47 (33) 18 (38) 21 (45) 8 (17) ns
Sigma 26 (18) 5 (19) 13 (50) 8 (31)
Rectum 68 (48) 14 (21) 35 (52) 19 (28)
T-category [n (%)]
pT1 10 (7) 2 (20) 6 (60) 2 (20) ns
pT2 17 (12) 2 (12) 11 (65) 4 (24)
pT3 99 (70) 30 (30) 44 (44) 25 (25)
pT4 15 (11) 3 (20) 8 (53) 4 (27)
Tumor diameter (mm) [mean ± SD]
All 47.4 ± 23.0 42.4 ± 12.0 50.8 ± 29.1 46.03 ± 16.9 ns
Men 47.0 ± 19.5 40.2 ± 12.3 52.3 ± 23.9 47.1 ± 17.3 .058
Women 47.9 ± 27.5 47.6 ± 10.2 49.3 ± 33.5 43.7 ± 16.7 ns
Number of lymph nodes [mean ± SD]
Studied 15.9 ± 5.8 15.7 ± 4.6 16.1 ± 6.2 15.5 ± 6.4 ns
With metastases 2.5 ± 4.1 2.5 ± 3.3 2.0 ± 4.1 3.3 ± 4.9
Men 2.5 ± 3.7 2.9 ± 3.7 1.6 ± 2.9 3.3 ± 4.7
Women 2.4 ± 4.7 1.7 ± 2.1 2.3 ± 5.0 3.5 ± 5.7
N-category [n (%)]
pN0 69 (49) 16 (23) 38 (55) 15 (22) ns
pN1 37 (26) 10 (27) 19 (51) 8 (22)
pN2 35 (25) 11 (31) 12 (35) 12 (35)
M-category [n (%)]
pM0 113 (80) 31 (27) 56 (50) 26 (23) ns
pM1 28 (20) 6 (21) 13 (46) 9 (32)
UICC tumor stage [n (%)]
IA 20 (14) 3 (15) 12 (60) 5 (25) ns
IB 36 (25) 10 (28) 18 (50) 8 (22)
II 3 (2) 0 3 (100) 0
IIIA 4 (3) 0 3 (75) 1 (35)
IIIB 24 (17) 9 (38) 12 (50) 3 (13)
IIIC 26 (18) 9 (35) 8 (31) 9 (35)
IV 28 (20) 6 (21) 13 (46) 9 (32)
ns, statistically not significant.
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50-ml reaction mixture consisted of 25 ml of HotStarTaq
Master Mix (Qiagen), 100 ng of genomic DNA, 250 pmol of
each primer (ACE-US: 5V-CTggAgACCACTCCCATCCT-
TTCT; ACE-DS: 5V-gATgTggCCATCAC-ATTCgTCAgAT),
and 5% (vol/vol) DMSO. An initial 15-minute denaturation
at 95jC was followed by 40 cycles of 1 minute at 64jC,
1 minute at 72jC, and 0.6 minute at 94jC. Amplified ACE
gene fragments were separated on 1.6% agarose gels and
visualized by ethidium bromide staining. D-alleles or I-alleles
were identified by the presence of 190-bp or 490-bp frag-
ments, respectively. The ID genotype commonly shows a
double band at 490 bp and a single band at 190 bp [21]. An
independent PCR analysis was carried out for each sample.
Statistical Analysis
Statistical analysis was carried out with SPSS software,
Version 14.01 (Chicago, IL). Values are expressed asmean ±
standard deviation (SD). The independence of qualitative
outcomes was tested using Pearson’s chi-square test and
Fisher’s exact test, where appropriate. One-way analysis of
variance and t-test were used for the comparison of group
means. The dependency of patient survival on ACE geno-
type was evaluated using the Kaplan-Meier method and was
compared using log-rank test. P < .05 (two-tailed) was con-
sidered ‘‘significant.’’
Results
Expression of ACE in Nonlesional Colon Mucosa,
Adenomas, and Colorectal Carcinomas
The local expression of ACE in CRCs and corresponding
nonlesional tissues was studied at the mRNA and protein
levels. As shown in Figure 1, ACE mRNA was highly signif-
icantly upregulated in colon carcinomas compared to corre-
sponding nonlesional tissues (2.5-fold; P = .009).
Immunohistochemistry was performed on paraffin-
embedded tissue sections from 22 of 141 patients (see
below) with CRC and from 21 patients with colorectal ade-
nomas. We examined the expression of ACE in the nontu-
morous crypt and surface epithelium, endothelial cells, and
carcinomas. ACE was significantly more commonly ex-
pressed in CRC cells [22 (100%)] than in non-neoplastic
crypt and surface epithelium [2 (9%)]. Immunostaining was
usually moderate to strong, and was confined to the apical
membrane of tumor cells [19 (86%)] and/or the cytoplasm [21
(95%)] (Figure 2). ACE was already expressed by neoplastic
cells of colorectal adenomas [17 (81%)]. However, in adeno-
mas, expression was usually weak and mainly localized in
the cytoplasm [17 (81%)], and less commonly at the apical
membrane [9 (43%)]. ACE was found in endothelial cells of
the tumor vessels of all (100%) patients (Figure 2).
ACE Gene Polymorphism
ACE gene polymorphism was studied in 141 CRC pa-
tients and was compared with that of 189 individuals without
cancer (Figure 3). The control group had been published pre-
viously [17]. Table 1 summarizes the clinical characteristics.
The mean age of colon cancer patients (including 83 men and
58 women) was 66.7 ± 12.4 years, and the mean age of con-
trol patients (including 75 men and 114 women) was 67.7 ±
6.1 years. Although the control group included significantly
more women than the CRC group, gene polymorphism was
not associated with patient gender in the control population.
Thirty-seven (26%) of 141 patients with CRC had the II ge-
notype, 69 (49%) had the ID genotype, and 35 (25%) had the
DD genotype. The distribution of the ACE genotypes did not
differ significantly from the control group or from the distri-
bution predicted by the Hardy-Weinberg equilibrium (Table 1).
Univariate analyses showed that the ACE genotypes
were associated with patient gender in the CRC group.
Women more commonly carried the ID genotype and less
frequently the II and DD genotypes compared with men (P =
.033). Furthermore, in men, the mean metric tumor diameter
was higher in carriers of the ID and DD genotypes. However,
this did not reach statistical significance. Therefore, we
dichotomized male CRC patients into carriers homozygous
for the II-allele and carriers heterozygous or homozygous for
the D-allele (Table 2). This demonstrated that the D-allele
was associated with a significantly higher mean metric tumor
diameter than homozygosity for the II-allele (P < .01; Table 2).
No gender-dependent or gender-independent correlation
was found between tumor location (colon versus sigma
versus rectum), depth of local tumor invasion (T-category),
nodal spread (N-category), distant metastases (M-category),
UICC tumor stage, and ACE genotype.
Finally, we studied the influence of the ACE genotypes on
patient survival (Table 3). Follow-up data were available from
104 patients (65 men, 39 women). Overall patient survival
correlated, although not significantly, with the ACE I/D gene
polymorphism. Carriers homozygous for the I-allele lived
shorter (mean survival, 38.04 ± 4.75 months) than carriers
of the D-allele (46.37 ± 4.90 months; Figure 4, A–C). Inter-
estingly, this difference was mainly related to female gender.
Figure 1. Expression of ACE mRNA in colon carcinoma and nonlesional
tissues. ACE expression was measured by quantitative real-time RT-PCR
and normalized against -actin. Box boundaries: 25th and 75th percentiles;
solid line: median; whiskers: lowest and highest nonoutlier values. **P < .01.
TU, tumor; NT, nontumorous mucosa.
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Womenwith the DD genotype had the best prognosis (61.02 ±
1.69 months) compared with women carrying the ID genotype
(43.53 ± 5.27 months) or women carrying the II genotype
(25.99 ± 5.64 months; Figure 4C). After the dichotomization of
the patient population into carriers homozygous for the II-allele
and carriers heterozygous (ID) or homozygous for the D-allele
(Figure 4, D–F ), the correlation between ACE polymorphism
and patient survival was still apparent for women (25.99 ±
5.64 vs 47.21 ± 4.53 months; Figure 4F ).
Discussion
CRC affects approximately 6% of the population and is the
second leading cause of cancer-related deaths in the United
States and Europe. In 2003, approximately 150,000 new
cases of CRC were diagnosed in the United States, and
57,100 individuals died from this disease. Until today, most
cases are detected in advanced stages, in which curative
treatment is not possible and chemotherapy remains the
only, but unsatisfying, option. Thus, improving early diagno-
sis and finding new treatment strategies still are of para-
mount importance in CRC [22–24].
Recently, we have shown that ACE is expressed locally in
gastric cancer [16] and that the I/D gene polymorphism of the
ACE gene influences tumor development [25] and metastatic
Figure 2. Expression of ACE in CRC. The distribution and expression pattern of ACE in non-neoplastic colon mucosa (A and B) and colorectal carcinomas (C and
D) was investigated by immunohistochemistry. ACE was found in (B and D) endothelial cells and (D) tumor epithelial cells. Hematoxylin and eosin (A and C);
monoclonal anti-ACE antibody (B and D); hematoxylin counterstain. Original magnification, 400.
Figure 3. Determination of ACE genotypes by PCR amplification. Amplified
ACE gene fragments were separated on 1.6% agarose gels and visualized by
ethidium bromide staining. D-alleles or I-alleles were identified by the pres-
ence of 190-bp or 490-bp fragments, respectively. bp, molecular-weight markers.
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behavior [17]. Furthermore, the retrospective study provided
evidence that long-term ACE medication decreases the risk
of developing CRC [18]. Intrigued by these findings, we
aimed to further substantiate the putative significance of
ACE in gastrointestinal cancer biology by investigating its
local expression in CRC and the correlation between ACE
gene polymorphism and CRC progression.
We believe that we are the first to show that CRCs
differentially express ACE in tumor cells at the mRNA and
protein levels, whereas non-neoplastic surface and crypt
epithelium rarely express any ACE. Interestingly, ACE was
primarily localized at the apical membrane and in the cyto-
plasm of tumor cells, and not at the basolateral surface. This
leads to the conjecture that ACE might be involved in au-
tocrine or paracrine tumor cell homeostasis rather than tu-
mor cell invasion (e.g., matrix degradation and remodeling).
ACE is a type I integral membrane protein with a catalytic site
exposed to the extracellular surface. Considerable amounts
of ACE are expressed by epithelial cells of the small intes-
tine, but also in the chief cells of the gastric foveolar epithe-
lium [16,26–29], where it may play a role in the metabolism
of gastrointestinal hormones and regulatory peptides [30,
31]. Being a relatively nonspecific enzyme, ACE cleaves a
number of synthetic and naturally occurring substrates.
Thus, differential upregulation of ACE in CRCs may poten-
tially influence tumor cell biology. In addition, ACE was also
strongly expressed in endothelial cells of tumor vessels, lead-
ing us to suggest that it may be additionally involved in the
neoangiogenesis of CRC.
To further substantiate the putative impact of ACE on
CRC biology, we then investigated the correlation of the ACE
I/D gene polymorphism with various tumor characteristics.
The polymorphism in the ACE gene accounts for 20% to 50%
of the variance in ACE expression or activity in blood and
tissues among individuals and influences its pathophysiolog-
ical function in diseases such as hypertension [32], athero-
sclerotic cardiovascular complications [33], and diabetic
nephropathy [34]. The distribution of different ACE gene
alleles in our entire CRC population did not differ from the
distribution in the general population, indicating that the over-
all risk of developing CRC is not linked to a specific ACE
genotype and, hence, enzyme expression or activity. How-
ever, the distribution of individual genotypes among men and
women was significantly different, suggesting that the ACE
genotype may have a gender-specific impact on CRC cancer
risk or progression. This is in line with a recent study pub-
lished by Reyes-Engel et al. [35], who found significant ACE
genotype–dependent differences in the serum levels of
angiotensin I and angiotensin 1–7. The gender-dependent
influence of ACE on tumor biology was further substantiated
by correlating tumor size with the ACE genotypes. Men
carrying the D-allele had significantly larger tumors than
men homozygous for the I-allele. A similar observation was
made in premenopausal women with breast cancer. Female
carriers of the D-allele had significantly larger breast can-
cers than carriers of the I-allele [36]. The absolute size of a
primary tumor depends on tumor cell proliferation and neo-
angiogenesis. Both may be influenced by ACE because
tumor cells and tumor vessels express ACE. Interestingly,
we did not find a correlation between ACE genotype and
tumor size in our female patients, who (different from the
study on breast cancer published by Yaren et al. [36]) were
primarily postmenopausal in our series. However, a correla-
tion was found when ACE gene polymorphism was correlated
with patient survival, and, here, women with the DD genotype
had the best prognosis. These seemingly contradictory obser-
vations may be related to the hormonal modulation of ACE
activity. In postmenopausal women, the DD genotype is as-
sociated with endothelial dysfunction, which may also influ-
ence CRC vasculature and tumor growth [37,38]. This might
further explain why the DD genotype is underrepresented in
our femalepatients comparedwithmaleCRCpatients. In post-
menopausal women, the DD genotype seems to protect from
the tumor progression of CRC.
Although ACE gene polymorphism was not linked to the
T-category, N-category, or M-category, it correlated with pa-
tient survival, indicating that ACE may be involved in disease
progression. However, due the small number—particularly
of women—in our series, we were unable to demonstrate
statistical significance. Therefore, future validation studies
should focus on the female patient population.
Different from observations made previously in gastric
cancer patients, we were unable to find any correlation
between the ACE genotypes and nodal spread in CRC. This
probably stems from the overall lower number of lymph node
metastases observed in CRC. The CRC patients in our
present series had a considerably lower number of lymph
node metastases (mean, 2.5 ± 4.1; median, 1.0) than the
gastric cancer patients (mean, 6.9 ± 9.0; median, 4.0)
studied previously [17].
Table 2. Mean Metric Tumor Size of CRC in Men and Women Dichotomized
into Carriers with and without the D-Allele.
Gender I/D Genotype n (%) Mean ± SD (mm) P
Men II 26 (31) 40.2 ± 12.2 < .01
ID + DD 57 (69) 50.1 ± 21.4
Women II 11 (19) 47.6 ± 10.2 ns
ID + DD 47 (81) 47.9 ± 30.3
Table 3. Mean Survival of Patients with CRC, By ACE Genotype.
Gender n (%) I/D Genotype Survival (Months)
[Mean ± SD]
P
Whole study population 29 (28) II 38.04 ± 4.75 .508
48 (46) ID 45.29 ± 3.94
27 (26) DD 46.37 ± 4.90
75 (72) ID + DD 46.13 ± 3.13 .250*
Men 22 (34) II 40.06 ± 5.54 .704
22 (34) ID 47.95 ± 5.63
21 (32) DD 42.53 ± 5.86
43 (66) ID + DD 45.96 ± 4.20 .587*
Women 7 (18) II 25.99 ± 5.64 .141
26 (67) ID 43.53 ± 5.27
6 (21) DD 61.02 ± 1.69
32 (82) ID + DD 47.21 ± 4.53 .141*
*II versus ID + DD.
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Our observations may also provide putative explanations
to the findings of a retrospective study where ACE medica-
tion was associated with a significantly reduced risk of
developing CRC [18]. It is now widely accepted that CRCs
frequently arise from preneoplastic lesions (i.e., adeno-
mas)—through activation of oncogenes (k-ras) and inactiva-
tion of tumor-suppressor genes (APC, p53, and DCC)—and
DNA mismatch repair genes [39]. Therefore, we finally stud-
ied the expression of ACE in colorectal adenomas. ACE was
expressed in colorectal adenomas showing expression pat-
terns similar to those in CRC. Thus, based on our observa-
tions and the findings made in a retrospective study, we
hypothesize that ACE contributes to the progression of colo-
rectal adenomas to CRC by influencing local tumor growth
Figure 4. Kaplan-Meier survival curves for the ACE I/D gene polymorphism in CRC patients. Patient survival is shown for the whole study population in (A) and (D),
for men in (B) and (E), and for women in (C) and (F) across all genotypes (A–C), or for the dichotomization of the patient population into carriers homozygous for
the II-allele and carriers heterozygous (ID) or homozygous for the D-allele (D–F). Gender difference was noted. Women with the DD genotype lived longer than
women with the ID or II genotype. The x-axis denotes survival time (months), and the y-axis denotes survival probability.
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and neoangiogenesis. ACE inhibitors might interfere with this
effect, and further studies into this topic are warranted.
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